Serum Levels of Apelin, Chemerin and Adiponectin Adipokines in Irritable Bowel Syndrome and Healthy Subjects

Amir Abbasnezhad

Status: Completed

Conditions: Irritable Bowel Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT03366389

Lums.REC.1396.266

Details and patient eligibility

About

In this observational case-control study investigators aimed to assess the serum levels of adipokines such as Apelin, Chemerin and adiponectin in patients with irritable bowel syndrome (IBS), and compare it with healthy controls. Furthermore, investigators evaluated the possible correlation of these adipokines with IBS-QoL, IBSSS, GI symptoms and other clinical and psychological disorders.

Enrollment: 114 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Men and women between the ages of 18, and 80 years.
• IBS patients diagnosed according to the Rome III Diagnostic Criteria for Functional GI Disorders.

Exclusion criteria

• Any evidence of abdominal surgery or radiation
• celiac disease, or other primary GI illnesses
• GI infection obscuring IBS symptoms,
• using total parenteral nutrition therapy in the last 6 months
• pregnancy and lactation
• alcohol consumption
• concurrent chronic diseases such as diabetes, renal failure
• diagnosed and/or treated malignancy in the past 5 years
• anti-inflammatory drugs usage
• intake of vitamin D, omega-3, vitamin E, and calcium supplements
• being on a special diet or medication regimen during the last 6 months

Trial design

114 participants in 2 patient groups

Case

Description:

patients with irritable bowel syndrome

Control

Description:

Healthy subjects without any gastrointestinal disorders, chronic diseases and malignancy.